Evolus Net Total Equity Issued/Repurchased 2016-2024 | EOLS
Evolus net total equity issued/repurchased from 2016 to 2024. Net total equity issued/repurchased can be defined as the sum of all preferred and common equity transactions regarding a company's own stock.
| Evolus Annual Net Total Equity Issued/Repurchased (Millions of US $) |
|
|---|---|
| 2024 | $56 |
| 2023 | $0 |
| 2022 | $1 |
| 2021 | $104 |
| 2020 | $N/A |
| 2019 | $73 |
| 2018 | $124 |
| 2017 | $N/A |
| 2016 | $N/A |
| 2015 | $N/A |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | MED PRODUCTS | $0.779B | $0.266B |
| Evolus, Inc. is a medical aesthetics company. It focuses on providing physicians and patients in aesthetic procedures and treatments. The company focuses on the self-pay aesthetic market and its lead product candidate, DWP-450, is an injectable 900 kDa purified botulinum toxin type A complex. Evolus, Inc. is based in Irvine, California. | |||